CALGARY, AB, April 11, 2024 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), a pioneering Canadian company with a primary focus on advancing innovative psychedelic-assisted therapy (PaT) […]
Read more
CALGARY, October 24, 2023 – ATMA Journey Centers Inc. (“ATMA”), a Canadian company with a primary focus on advancing psychedelic-assisted therapy, is […]
Read more
ATMA and Cena Life Announce Joint-Venture to Support Psychedelic-Assisted Therapy in Canada CALGARY, October 20, 2023 – ATMA Journey Centers Inc. (“ATMA”), […]
Read more
As psychedelic therapy regulations are being implemented, drafted and discussed globally, the need to educate doctors, psychiatrists and prescribers in psychedelics is greater than ever.
Read more
In response to Australia’s approval of MDMA and psilocybin use in therapy AUSTRALIA, Feb. 7, 2023 /PRNewswire/ — ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, is […]
Read more
ATMA will use Filament’s proprietary botanical drug candidate for clinical trials
Read more
The program will support greater accessibility and affordability for clients and enable therapists to share data and experiences among colleagues to increase the efficiency and effectiveness of Psychedelic-assisted Therapy.
Read more
MDMA studies combined with psychoanalysis have shown great promise in the treatment of Posttraumatic Stress Disorder (PTSD), indicating sustained decreases in PTSD symptoms.
Read more
ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada’s Section 56(1) Exemption.
Read more
The completed equity investment strengthens ties between MINDCURE and ATMA.
Read more
BACK TO TOP